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Abstract There is evidence that 1-methyl-4-phenyl-1,2,3,6
tetrahydropyridine (MPTP) toxicity is mediated through both
inhibition of mitochondrial complex I and free radical genera-
tion. 7-Nitroindazole protects against MPTP toxicity in vitro
and in vivo, and this appears to be related to its inhibition of
nitric oxide (NO) synthase. We now show that the NO
generator, glutathione-N-oxide, enhances the inhibitory action of
1-methyl-4-phenylpyridinium (MPP) on complex I activity in
brain submitochondrial particles. We propose that the NO-
induced reversible inhibition of complex IV (cytochrome oxidase)
potentiates the MPP-induced irreversible free radical-mediated
inhibition of complex I. Thus, NO may ‘prime’ the respiratory
chain to the effects of MPP. These data provide evidence for an
interaction between NO and MPP at the level of the
respiratory chain. ß 2001 Federation of European Biochemi-
cal Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
The mechanisms of action of 1-methyl-4-phenyl-1,2,3,6-tet-
rahydropyridine (MPTP) have provided valuable insights into
the biochemical abnormalities that might participate in dopa-
minergic cell death in Parkinson’s disease (PD). 1-Methyl-4-
phenylpyridinium (MPP), the active metabolite of MPTP,
inhibits NADH CoQ1 reductase (complex I) of the mitochon-
drial respiratory chain [1], and de¢ciency of this enzyme has
been identi¢ed in the substantia nigra of PD brains [2^4].
There is also evidence of oxidative stress and damage in PD
substantia nigra [5], and that free radicals may play a role in
mediating the e¡ects of MPP toxicity [6^9].
The mitochondrial respiratory chain is responsible for a
signi¢cant proportion of a cell’s superoxide production during
aerobic respiration. Inhibition of respiratory chain activity by
mitochondrial toxins results in increased O2 generation [10].
Free radicals themselves are capable of causing respiratory
chain defects, primarily involving complexes I and IV in
vivo [11,12] and complexes I^III in vitro [13^15]. We have
shown in previous studies that if electron transport through
the respiratory chain is blocked by inhibition of complex IV,
MPP induces a severe, irreversible and selective inhibition of
complex I which is mediated via free radical release [7]. NO
has been shown to be a potent but reversible inhibitor of
complex IV [16,17], in addition to inhibiting complex II and
to a lesser extent complexes I and III of the respiratory chain
[18,19]. Thus, NO and MPP might theoretically combine
their e¡ects on the respiratory chain to induce irreversible
complex I inhibition. MPP and NO have been shown to
act synergistically in the release of calcium from, and the
depolarisation of, isolated mitochondria [20]. It was proposed
that the synergism may involve the formation of peroxynitrite
promoted by the increased superoxide formation induced by
complex I inhibition in the presence of NO.
Neurones containing neuronal NO synthase (NOS) have
been demonstrated in the striatum [21] and in the substantia
nigra [22], and therefore there is scope for both MPP and
NO to co-exist in the brain regions associated with PD. Fur-
thermore, 7-nitroindazole, an inhibitor of NOS, has been
shown to protect against MPTP toxicity in primates [23]
and mice [24]. Although 7-nitroindazole is also an inhibitor
of monoamine oxidase-B [25], it still reduces the toxicity of
MPP, and so must have an action beyond preventing the
conversion of MPTP to MPP [26]. We have investigated
the combined actions of MPP and NO on respiratory chain
function to determine if there is a direct interaction between
these agents at the level of complex I function.
2. Materials and methods
Unless otherwise stated, reagents were purchased from Sigma
Chemicals (Poole, Dorset, UK) or Merck (Dagenham, Essex, UK).
2.1. Puri¢cation of rat brain mitochondria and preparation of
submitochondrial particles (SMP)
SMP were made from rat forebrains as described previously [19]
and the SMP pellet resuspended at approximately 1 mg/ml, frozen in
small aliquots and stored at 370‡C until used.
2.2. Treatment of SMP with MPP and GSNO
Rat brain SMP were incubated at 0.1 mg/ml for 60 min in a bu¡er
containing 10 mM Tris^HCl, pH 7.4, 320 mM sucrose, 1 mM potas-
sium EDTA, and 0.8 mM NADH and 0.8 mM dithiothreitol (DTT)
at 28‡C. Glutathione-N-oxide (GSNO, from Alexis Corporation, Not-
tingham, UK) was used as the source of NO and was added to
reactions just prior to the incubation at concentrations indicated in
Section 3. The presence of DTT was required for the generation of
NO from GSNO. We have previously shown that DTT or decom-
position products of GSNO other than NO have no e¡ect on mito-
chondrial respiration [17]. MPP iodide (0.2 mM), 0.3 mM reduced
glutathione (GSH), 50 Wg/ml catalase, 0.3 M urate, 15 mM reduced
oxyhaemoglobin, made from haemoglobin according to Di Iorio [27],
and 100 U/ml Mn superoxide dismutase were added as indicated.
Aliquots (20 Wl) of the incubation were assayed for NADH CoQ1
reductase activity.
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2.3. Assay of NADH CoQ1 reductase activity
NADH CoQ1 reductase (complex I) was assayed spectrophotomet-
rically in a ¢nal volume of 1 ml at 28‡C [28]. Protein concentrations
were determined using the method of Lowry et al. [29] using bovine
serum albumin as standard.
2.4. Estimation of rate of production of NO by GSNO
The production of NO was analysed using a nitric oxide analyser,
model number NOA 280 (Sievers Instruments, Boulder, CO, USA).
Brie£y, a stream of pure N2 gas (£ow rate 200 ml/min) was passed
through a frit into a reaction chamber. This contained 3.4 ml of 10
mM Tris^HCl, pH 7.4, 320 mM sucrose, 1 mM potassium EDTA, 0.8
mM NADH and 0.8 mM DTT at 28‡C. Following a 5 min equilibra-
tion period, 100 Wl of the same bu¡er containing a solution of GSNO
was added to give a ¢nal concentration that was 1 mM with respect to
GSNO. The gas was taken from the top of the reaction vessel into the
detector, where it was mixed with O3. The resultant activated, NO2,
gave o¡ light as it decayed to its ground state NO2. This was detected
and a reading of NO in parts per billion was given based on a
calibration of the machine with authentic NO. Data were collected
for 1 h and the rate of NO production determined, using the value of
22.4 l as the molar gas volume at standard temperature and pressure
and the £ow rate of carrier gas.
3. Results and discussion
Using 1 mM GSNO as the source of NO, the rate of
production of NO was calculated to be 0.36 Wmol/kg/h at
its peak rate (approximately 3 min after addition of 1 mM
GSNO), falling exponentially to 0.15 Wmol/kg/h after 20 min.
There was negligible NO production thereafter. These ¢gures
are in the same range (0.33^0.85 Wmol/kg/h) reported for stud-
ies on whole rats [30] using an isotopic (16O2/18O2) ratio meth-
od in a closed system. In addition, ex vivo (cryogenic electron
paramagnetic resonance) measurements in normal rat brain
using spin-trapped NO gave a control value of 1.1 Wmol/
kg/h [31].
Incubation of SMP with 1 mM GSNO for 60 min did not
a¡ect complex I activity, while 10 mM MPP alone caused a
31% decrease in complex I activity (Fig. 1). This has previ-
ously been shown to be due to residual MPP (0.2 mM) in the
sample, following dilution into the assay bu¡er [7]. Co-incu-
bation of 1 mM GSNO and 10 mM MPP induced a 63%
inhibition of complex I activity indicating that the inhibitory
e¡ects of NO and MPP on complex I activity are synergis-
tic. MPP interacts reversibly with rotenone binding site(s)
within complex I [32] and results in superoxide generation
[7,33]. In the presence of complex IV inhibition, however,
the MPP inhibition of complex I activity is irreversible and
is mediated by free radical damage [7]. While complexes II
and III have been identi¢ed to be most susceptible to irrevers-
ible NO-induced inhibition [19], NO also causes a marked
reversible inhibition of complex IV activity [17], thereby gen-
erating the conditions previously reported for MPP to cause
increased free radical production and irreversible complex I
inhibition [7]. To determine what role free radicals play in the
complex I inhibition reported here, rat brain SMP were incu-
bated with MPP (10 mM), and a range of free radical scav-
engers in the presence and absence of GSNO (1 mM). As in
previous experiments using the complex IV inhibitor cyanide
[7], we found that in the presence of NO, the MPP-induced
decrease in complex I activity could be prevented by either
GSH or catalase (Fig. 2). This suggested that free radical
damage was involved in the MPP-induced irreversible inhi-
bition of complex I. It is proposed that MPP inhibition of
complex I resulted in increased superoxide generation which
in turn dismutated to hydrogen peroxide. In the likely event of
the presence of free iron, Fenton chemistry would lead to the
decomposition of hydrogen peroxide, generating the highly
reactive hydroxyl radical and subsequent oxidative damage
to neighbouring molecules including complex I itself. HbO2,
which scavenges NO, was also protective, con¢rming the
requirement for NO in mediating the complex I inhibition.
NO and O32 react at near di¡usion rates to form peroxyni-
trite (ONOO3), a highly reactive and damaging free radical
[34] which may contribute to respiratory chain inhibition
[35,36]. However, urate, which scavenges ONOO3, did not
protect the enzyme activity, suggesting that ONOO3 was
not involved directly in the inhibition of complex I. It must
be noted however that urate, upon reaction with ONOO3,
can give rise to aminocarbonyl radicals [37]. These radicals
could attack lipids and thus a¡ect membrane-associated en-
zymes. The lack of protection by urate therefore must be
viewed with caution. The synergistic action of NO on
MPP inhibition of complex I may help explain some of the
data on the protective e¡ect of 7-nitroindazole against MPTP
toxicity. In the absence of NO, MPP-induced inhibition of
Fig. 1. Rat brain SMP were incubated at 0.1 mg ml31 for 60 min
in a sucrose^Tris bu¡er, pH 7.4, containing NADH (0.8 mM) and
combinations of GSNO (1 mM) and MPP (10 mM). The activity
of the enzyme NADH CoQ1 reductase was measured in samples of
the incubation mixture. The results are expressed as the mean of at
least three incubations þ S.D. *P6 0.0001 relative to the control or
GSNO alone and P6 0.002 relative to MPP alone (unpaired
t-test).
Fig. 2. Rat brain SMP were incubated at 0.1 mg ml31 for 60 min
in a sucrose^Tris bu¡er, pH 7.4, containing 10 mM MPP and 0.8
mM NADH in the presence or absence of 1 mM GSNO. In addi-
tion, a variety of reagents were also added separately to the reac-
tion: GSH, urate, catalase, superoxide dismutase or oxyhaemoglo-
bin. The ¢lled bars indicate incubations lacking GSNO; the open
bars incubations with GSNO. The results are expressed as the mean
of at least three incubations þ S.D. *P6 0.02, **P6 0.001 relative
to the respective control (unpaired t-test).
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complex I may be insu⁄cient to lower ATP to the critical
levels that may induce cell death. In the brain it is possible
that MPP itself may potentiate the interaction of MPP and
NO by promoting the generation of NO. The ATP decrease
caused by MPP inhibition of complex I could enhance glu-
tamate toxicity through release of the Mg2 blockade of
N-methyl-D-aspartate receptors. The resulting calcium in£ux
could activate neuronal NOS and NO production, resulting
in enhanced complex I inhibition by the mechanisms outlined
above. As the striatum is richly supplied with NOS positive
neurones, and NMDA receptors [38] and MPP enter
through nerve terminals [39], the striatum is likely to be the
source of greatest NO and MPP toxicity. Direct parallels
between MPTP toxicity and idiopathic PD must be drawn
with care. There is as yet no direct evidence of NO involve-
ment in dopaminergic cell death in PD, although there is
accumulating evidence to support NO generation in the PD
brain [40]. Using electron paramagnetic resonance, one study
showed increased levels of nitrosyl proteins in PD striatum
[41] and nitrotyrosine residues have been identi¢ed in Lewy
bodies in PD brain. Complex I de¢ciency in PD brain appears
to be con¢ned to, or at least most severe in, the substantia
nigra [42]. These factors would suggest that NO could con-
tribute to a dying-back degeneration perhaps initiated by a
putative MPTP-like toxin that might enter via dopamine ter-
minals in the striatum and be concentrated within the cell
body in the substantia nigra.
GSH de¢ciency has been described in PD substantia nigra
[5] and may be an early event in pathogenesis [43]. While the
decrease in GSH may be a consequence of free radical gen-
eration, it may also re£ect the vulnerability of surviving neu-
rones as complex I has been shown to be more sensitive to
inhibition at low GSH levels [44]. In addition, we have dem-
onstrated the protective e¡ect of GSH against NO/MPP
toxicity in our in vitro model.
In conclusion, our data provide a novel means of interac-
tion between NO and MPP and suggest that complex I
inhibition may be a target in a common pathway leading to
nigrostriatal neuronal damage.
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